Literature DB >> 25411807

Obesity and polycystic ovary syndrome.

N Naderpoor1, S Shorakae, A Joham, J Boyle, B De Courten, H J Teede.   

Abstract

Obesity is now a major international health concern. It is increasingly common in young women with reproductive, metabolic and psychological health impacts. Reproductive health impacts are often poorly appreciated and include polycystic ovary syndrome (PCOS), infertility and pregnancy complications. PCOS is the most common endocrine condition in women and is underpinned by hormonal disturbances including insulin resistance and hyperandrogenism. Obesity exacerbates hormonal and clinical features of PCOS and women with PCOS appear at higher risk of obesity, with multiple underlying mechanisms linking the conditions. Lifestyle intervention is first line in management of PCOS to both prevent weight gain and induce weight loss; however improved engagement and sustainability remain challenges with the need for more research. Medications like metformin, orlistat, GLP1 agonists and bariatric surgery have been used with the need for large scale randomised clinical trials to define their roles.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25411807

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  22 in total

Review 1.  Evidence for a Coupled Oscillator Model of Endocrine Ultradian Rhythms.

Authors:  Azure D Grant; Kathryn Wilsterman; Benjamin L Smarr; Lance J Kriegsfeld
Journal:  J Biol Rhythms       Date:  2018-08-22       Impact factor: 3.182

Review 2.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

Review 3.  Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.

Authors:  Shikha Rani; Piyush Chandna
Journal:  Reprod Sci       Date:  2022-01-27       Impact factor: 3.060

Review 4.  Developmental Programming of Ovarian Functions and Dysfunctions.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

Review 5.  Gestational Hyperandrogenism in Developmental Programming.

Authors:  Christopher Hakim; Vasantha Padmanabhan; Arpita K Vyas
Journal:  Endocrinology       Date:  2017-02-01       Impact factor: 4.736

6.  Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.

Authors:  María Victoria De Diego; Olga Gómez-Pardo; Janette Kirk Groar; Alejandro López-Escobar; Irene Martín-Estal; Inma Castilla-Cortázar; Miguel Ángel Rodríguez-Zambrano
Journal:  Arch Gynecol Obstet       Date:  2020-08-08       Impact factor: 2.344

7.  A Potential Therapeutic Role of Myoinositol in the Metabolic and Cardiovascular Profile of PCOS Iranian Women Aged between 30 and 40 Years.

Authors:  Saghar Salehpour; Leila Nazari; Sedighe Hoseini; Nasrin Saharkhiz; Fatemeh Ghazi; Mohammad Reza Sohrabi
Journal:  Int J Endocrinol       Date:  2016-08-25       Impact factor: 3.257

Review 8.  The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.

Authors:  Wenjuan Shen; Bao Jin; Yaguang Han; Hongwei Wang; Huan Jiang; Linlin Zhu; Mei Han; Jiao Zhang; Yang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-15       Impact factor: 2.629

Review 9.  A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.

Authors:  Rajeshwari Kalyanaraman; Lubna Pal
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

10.  How to Screen and Prevent Metabolic Syndrome in Patients of PCOS Early: Implications From Metabolomics.

Authors:  Xiaoxuan Zhao; Xiaoling Feng; Xinjie Zhao; Yuepeng Jiang; Xianna Li; Jingyun Niu; Xiaoyu Meng; Jing Wu; Guowang Xu; Lihui Hou; Ying Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.